HALOBETASOL PROPIONATE
Clinical safety rating: safe
No significant drug interactions Systemic absorption can occur with extensive use leading to adrenal suppression.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Primarily hepatic via CYP450 enzymes, followed by renal excretion of metabolites. |
| Excretion | Primarily renal excretion of metabolites (approximately 60-70%) with biliary/fecal elimination accounting for 20-30%. Less than 5% excreted as unchanged drug in urine. |
| Half-life | Terminal elimination half-life is approximately 15-20 hours following topical application, though systemic absorption is minimal with intact skin. Prolonged half-life may occur with extensive use or impaired hepatic function. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin and to a lesser extent alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.5-1.5 L/kg after systemic absorption (e.g., from extensive topical use or oral administration). This high Vd indicates extensive tissue distribution, particularly to skin and adipose tissue. |
| Bioavailability | Topical absorption is highly variable (1-5% through intact skin, up to 30-50% through damaged or inflamed skin). Oral bioavailability is approximately 80-100% (not a typical route). |
| Onset of Action | Topical: Onset of anti-inflammatory and antipruritic effects occurs within 3-6 hours after application, with peak effects in 6-12 hours. |
| Duration of Action | Duration of action after a single topical application is 8-12 hours for anti-inflammatory effects. Clinical improvement may persist for 1-2 days after cessation due to drug residence in stratum corneum. Not intended for sustained therapy beyond 2 weeks without reassessment. |
Topical: Apply a thin film to affected areas twice daily (morning and evening). Maximum weekly dose should not exceed 50 g/week. Duration of therapy should be limited to 2 consecutive weeks.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No formal studies; caution in severe hepatic impairment due to potential systemic absorption and metabolism. |
| Pediatric use | Children (≥12 years): Apply a thin film to affected areas twice daily. Use the smallest amount possible. Not recommended for children <12 years due to higher systemic absorption. |
| Geriatric use | Use with caution; apply smallest amount for shortest duration due to increased risk of skin thinning and systemic effects. Avoid use in intertriginous areas. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use leading to adrenal suppression.
| FDA category | Animal |
| Breastfeeding | It is unknown if halobetasol propionate is excreted in human milk. Due to potential for serious adverse reactions in nursing infants (growth suppression, adrenal suppression), caution is advised. M/P ratio not available. The manufacturer recommends considering drug importance to mother and discontinuing nursing or drug. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to halobetasol propionate or any component","Untreated bacterial, fungal, viral, or parasitic infections at application site","Perioral dermatitis","Rosacea"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Cushing's syndrome","Hyperglycemia","Skin atrophy, striae, telangiectasia","Local irritation, allergic contact dermatitis","Use with caution on face, intertriginous areas, or under occlusive dressings"] |
Loading safety data…
| Halobetasol propionate is a highly potent corticosteroid. In pregnant women, systemic absorption may cause fetal harm. First trimester: Animal studies show teratogenicity (cleft palate, IUGR) with topical corticosteroids; human data limited but risk cannot be excluded. Second/third trimester: Prolonged use may lead to fetal adrenal suppression, low birth weight. Use only if benefit outweighs risk; avoid extensive areas or prolonged treatment. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (weight gain, glucose tolerance, blood pressure, electrolytes) if used extensively. In neonate, observe for adrenal suppression, growth retardation if maternal use was prolonged or high-dose. No specific fetal monitoring required unless systemic absorption suspected. |
| Fertility Effects | No specific human data on effects on fertility. Animal studies at high systemic doses have shown impaired fertility. Topical use with minimal absorption is unlikely to significantly affect fertility. |